Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284003 | 0.85 | HCRTR1 (0.41) | HCRTR1HCRTR2KDM4EL3MBTL1 | |
| SCHEMBL4287933 | 0.83 | HRH3 (0.44) | S1PR5OPRK1S1PR1HRH3 | |
| SCHEMBL4290115 | 0.83 | ALDH1A1 (0.45) | HCRTR1HCRTR2KDM4EL3MBTL1LMNA | |
| SCHEMBL4285580 | 0.83 | CPS1 (0.46) | HCRTR1HCRTR2KDM4ELMNA | |
| SCHEMBL4290199 | 0.83 | HCRTR1 (0.41) | HCRTR1HCRTR2KDM4EKCNH2GPR119 | |
| SCHEMBL4291196 | 0.83 | KDM4E (0.45) | HCRTR1HCRTR2KDM4EL3MBTL1KDM1A | |
| SCHEMBL4290602 | 0.81 | HCRTR1 (0.39) | HCRTR1HCRTR2KDM4EHRH3LMNA | |
| SCHEMBL4282070 | 0.81 | NPC1 (0.48) | HCRTR1HCRTR2KDM4EL3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL4302104 | 0.81 | KDM1A (0.36) | S1PR5KDM1ACXCR3KCNH2LTA4H | |
| Hydrochloric Acid SCHEMBL4286059 | 0.81 | KDM1A (0.36) | S1PR5KDM1ACXCR3KCNH2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885KDM4E 760/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885KDM4E 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.